25I-NBMD
From Wikipedia, the free encyclopedia
Jump to: navigation, search
Legal status | |
---|---|
Legal status |
|
Identifiers | |
Systematic (IUPAC) name: N-[(2H-1,3-benzodioxol-4-yl)methyl]-2-(4-iodo-2,5-dimethoxyphenyl)ethan-1-amine
|
|
CAS Number | 919797-25-4 N |
PubChem (CID) | 57507899 |
ChemSpider | 26234932 Y |
UNII | R99110126K N |
Chemical and physical data | |
Formula | C18H20INO4 |
Molar mass | 441.259 g/mol |
3D model (Jmol) | Interactive image |
|
|
|
|
NY (what is this?) (verify) |
25I-NBMD (NBMD-2C-I, Cimbi-29) is a derivative of the phenethylamine hallucinogen 2C-I, discovered in 2006 by a team at Purdue University led by David Nichols. It acts as a potent partial agonist for the 5HT2A receptor with a Ki of 0.049nM at the human 5HT2A receptor.[1][2][3] The corresponding 4-bromo analogue 25B-NBMD has been used for molecular dynamics studies on the shape of the 5-HT2A receptor.[4]
Legality[edit]
Sweden's public health agency suggested to classify 25I-NBMD as hazardous substance on November 10, 2014.[5]
References[edit]
- ^ Braden, MR; Parrish, JC; Naylor, JC; Nichols, DE (2006). "Molecular interaction of serotonin 5-HT2A receptor residues Phe339(6.51) and Phe340(6.52) with superpotent N-benzyl phenethylamine agonists". Molecular Pharmacology. 70 (6): 1956–64. doi:10.1124/mol.106.028720. PMID 17000863.
- ^ Michael Robert Braden PhD. Towards a biophysical understanding of hallucinogen action. Purdue University 2007.
- ^ Ettrup, A.; Hansen, M.; Santini, M. A.; Paine, J.; Gillings, N.; Palner, M.; Lehel, S.; Herth, M. M.; Madsen, J.; et al. (2010). "Radiosynthesis and in vivo evaluation of a series of substituted 11C-phenethylamines as 5-HT2A agonist PET tracers". European Journal of Nuclear Medicine and Molecular Imaging. 38 (4): 681–93. doi:10.1007/s00259-010-1686-8. PMID 21174090.
- ^ Isberg V, Balle T, Sander T, Jørgensen FS, Gloriam DE (February 2011). "G protein- and agonist-bound serotonin 5-HT2A receptor model activated by steered molecular dynamics simulations". Journal of Chemical Information and Modeling. 51 (2): 315–25. doi:10.1021/ci100402f. PMID 21261291.
- ^ "Cannabinoider föreslås bli klassade som hälsofarlig vara". Retrieved 29 June 2015.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Phenethylamines |
|
---|---|
Amphetamines |
|
Phentermines |
|
Cathinones |
|
Phenylisobutylamines | |
Phenylalkylpyrrolidines | |
Catecholamines (and close relatives) |
|
Miscellaneous |
|
This Hallucinogen-related article is a stub. You can help Wikipedia by expanding it. |
Retrieved from "https://en.wikipedia.org/w/index.php?title=25I-NBMD&oldid=747210068"
Hidden categories:
- Articles with changed CASNo identifier
- Articles with changed FDA identifier
- Chemical articles having calculated molecular weight overwritten
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Drugboxes with an unspecified ATC code
- Drugboxes which contain changes to verified fields
- Drugboxes which contain changes to watched fields
- All stub articles